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Abstract: 
Two new eudesmane sesquiterpenes, 2α-hydroxy pterodontic acid (1) and pterodolide [3α-(2-
methyl-2,3-epoxy)-butyric-4α-acetoxy-8β-ethoxy eudesma-7(11)-en-8α,12-olide (2), along with 
five known compounds (3–7) were isolated from the aerial parts of Laggera pterodonta. Their 
structures were elucidated on the basis of spectroscopic methods. The immunosuppressive 
activity of the isolated compounds was investigated. 
 
Article: 
INTRODUCTION 
Laggera pterodonta (DC.) Benth is a kind of medicinal plant growing in Yunnan province, and 
has been used as folk medicine from ancient times. Pharmacological research indicated that the 
extract of L. pterodonta has antileukaemia, anti-bacterial, anti-inflammatory and anti-malarial 
activities 1-3. In our search for pharmacologically active compounds from medicinal plants, the 
petroleum ether extract of L. pterodonta showed significant inhibitory effects on lymphocyte 
transformation (34.7%, 50 μg/ml). This paper deals with the isolation and structure elucidation of 
two new and five known compounds (1–7) from the aerial parts of L. pterodonta. Their 
immunosuppressive activities were evaluated. 
 
RESULTS AND DISCUSSION 
Compound 1 was obtained as an amorphous powder. A dehydrate molecular ion peak at m/z 
232.1439 [M–H2O]+ observed in the HREI-MS, indicated the molecular formula of C15H22O3 
for 1. Its IR spectrum showed the presence of hydroxyl groups (3398 cm− 1) and carbonyl group 
(1695 cm− 1). The 1H NMR spectrum of 1 revealed the presence of two methyl groups (δH 1.26, 
d, J = 7.6 Hz and 1.25, s), one oxygenated methine proton (δH 4.51, m), three olefinic protons 
(δH 6.54, d, J = 1.6 Hz; 5.68, br s, and δH 5.50, s). Its 13C NMR spectrum showed 15 carbons, 
including two methyls, one oxygenated methine (δC 63.3), four methylenes, and one double bond 
(δC 147.4, s; 125.2, d), as well as the α, β-unsaturated carboxylic acid (δC 170.1, s, 147.9, s, 
123.0, t). The 13C NMR spectrum of 1 was similar to those of 3β-hydroxy pterodontic acid (4), 
except for C–1 to C–4 [4]. 
 
Furthermore, in the HMBC spectrum of 1, H–1 at δH 2.16 and 1.48 correlated with C–2 at δC 
63.3, H–4 at δH 2.68 correlated with C–2 at δC 63.3, C–3 at 43.7, C–5 at 147.4, C–6 at 125.2, 
and C–10 at 35.9, and the methyl proton at δH 1.26 (H3–15) correlated with C–3 at δC 43.7, C–4 
at 39.9, and C–5 at 147.4, suggesting that the hydroxyl group was located at C–2. On the other 
hand, in the NOESY spectrum, H–2 at δH 4.51 correlated with 14-CH3 at δH 1.26 and 15-CH3 at 
1.25, indicating the hydroxyl group at C–2 has equatorial orientation. Based on above facts, 
compound 1 was deduced as 2-hydroxy pterodontic acid. 
 
Pterodolide (2) had a molecular formula of C24H34O8 as inferred from its HRFT-MS (m/z 
451.2329 [M+H]+). Its IR spectrum showed an intensive absorption 1755 cm− 1 for the 
unsaturated lactone. The 1H NMR spectrum of 2 revealed the presence of an acetyl group (δH 
2.00), an ethoxyl group (3.44, 3.30; each 1H, dq, J = 11.0, 7.0 Hz; 1.20, 3H, t, J = 7.0 Hz), one 
oxygenated methine (δH 5.83; 1H, br t, J = 2.7 Hz), as well as three methyl groups (δH 1.89, 
1.59, 1.20; each 3H, s). From HSQC and HMBC spectra, it also showed the presence of 2-
methyl-2,3-epoxy-butyric group (δH 3.05; 1H, q, J = 5.4 Hz; 1.29, 3H, d, J = 5.4 Hz; 1.52, 3H, 
s). The 13C NMR spectrum of 2 revealed seven methyls, two oxygenated methines, one 
oxygenated methylene, one ketal carbon (δC 105.7), and two carbonyl carbons (δC 169.1 and 
168.2), in addition to a α, β-unsaturated lactone moiety (δC 171.6, 159.3, 124.1). 
 
In the HMBC spectrum, the H–9a at δH 2.30 correlated with C–7 at δC 159.3, C–8 at 105.7, C–5 
at 50.3, and C–10 at 35.2, the H–6a at δH 2.89 correlated with C–7 at δC 159.3, C–8 at 105.7, and 
C–10 at 35.2, and 13-CH3 at δH 1.89 correlated with C–7 at δC 159.3, C–11 at 124.1, and C–12 
at 171.6. Therefore, the 8,12-olide partial structure was proposed, and eight degree unsaturations 
for 2 also supported the presence of a lactone ring. Furthermore, 15-CH3 at δH 1.59 correlated 
with C–3 at δC 73.3, C–4 at 82.7, and C–5 at 50.3, H–3 at δH 5.83 correlated with the carbonyl 
carbon signal at δC 168.2 (2-methyl-2,3-epoxy-butyric group), and the ethoxyl proton at δH 3.44 
and 3.30 correlated with C–8 at δC 105.7. Therefore, ethoxyl and 2-methyl-2,3-epoxy-butyric 
groups should be located at positions C–8 and C–3, respectively. The acetyl group would be 
assigned at C–4. From the above information, 2 was also assumed to be a eudesmane 
sesquiterpene lactone, similar to the structure of 1β,8β-dihydroxy eudesman 3,7(11)-dien-8α,12-
olide [5]. 
 
In the NOESY spectrum, the15-CH3 at δH 1.59 correlated with the 14-CH3 at δH 1.20 and H–3 
at 5.83, the acetyl methyl at δH 2.00 correlated with the H–5 at δH 1.76; the methylene signal of 
ethoxyl group at δH 3.44 and 3.30 correlated with the 14-CH3 signal at δH 1.20. Therefore, the 
structure of 2 was determined as pterodolide (figure 1). 
 
 
Figure 1: Structures of compounds 1–7. 
 
 
Five known compounds, 1β-hydroxy pterodontic acid (3) [4], 3β-hydroxy pterodontic acid (4) 
[4], pterodontic acid (5) [4], tessaric acid (6) [6], and dehydroabietic acid (7) [7], were identified 
by comparison of their spectroscopic data with those of literature values. 
 
Table 1: 1H NMR and 13C NMR spectral data of 1 and 2. 
No. 1 (C5D5N)  2 (CDCl3) δC  δH mult. (J=Hz)  δC  δH mult. (J=Hz) 
1 52.3 2.16, 1.48 m  33.6 1.33 m 
2 63.3 4.51 m  22.9 1.98 m 
3 43.7 2.16, 1.81 m  73.3 5.83 br t (2.7) 
4 39.9 2.68 m  82.7 – 
5 147.4 –  50.3 1.76 dd (12.0, 2.6) 
6 125.2 5.50 s  21.9 2.89 dd (12.8, 2.6), 2.20 dd (12.8, 12.0) 
7 39.6 3.74 m  159.3 – 
8 26.9 2.17, 1.50 m  105.7 – 
9 42.3 1.50, 1.59 m  53.5 2.30, 1.42 d (13.5) 
10 35.9 –  35.2 – 
11 147.9 –  124.1 – 
12 170.1 –  171.6 – 
13 123.0 5.68 br s, 6.54 d (1.6)  8.1 1.89 s 
14 28.7 1.25 s  19.1 1.20 s 
15 24.7 1.26 d (7.6)  17.9 1.59 s 
 
 
 
In a search for immunosuppressive activity, we examined the immunoinhibitory effect of these 
sesquiterpenes on lymphocyte transformation [8,9] (table 2). The values of inhibition percent of 
compounds 1, 4 and 5 revealed a significant distinction to the Con A control group (P < 0.05, 
n = 6), and showed an inhibitory effect on lymphocyte transformation by comparing with a 
reference compound (dexamethasone). 
 
Table 2: Inhibitory effects of compounds 1, 3–5, and 7. 
Compounds Inhibition (%) 80 μg/ml 20 μg/ml 5 μg/ml 
1  26.8 18.4 6.6 
3  − 13.6 − 10.3 6.2 
4  13.1 4.8 1.8 
5  11.1 10.3 5.7 
7  − 3.5 − 0.4 2.9 
 
Inhibition ratio of dexamethasone = 60.7% (50 μg/ml). 
 
 
EXPERIMENTAL 
General experimental procedures 
NMR spectra were performed on a Bruker Avance 300 instrument with teramethylsilane as an 
internal standard. HRFT-MS and EI-MS were obtained on a Bruker apexIII 7.0 Tesla and VG 
ZAB-HS instrument, respectively. Column chromatography was performed on silica gel 
(Qingdao Haiyang Chemical Co. Ltd.), Sephadex LH-20 (Amersham Pharmacia Biotech) and 
Toyopearl HW-40 (Tosoh). HPLC was a Jasco Gulliver Series with PU-1580 (pump), RI-1530 
and UV-1575 (detector). Preparative HPLC column was used as follows: ODS (YMC-Pack 
ODS-A, SH-343-5), GPC (Shodex, Asahipak GS-310, 20G, MeOH). IR spectra were recorded 
on a FTS3000 Infrared Fourier Transform sepectrometer (Bio-Rad). Optical rotation was 
measured with a MC 241 digital polarimeter (Perkin Elmer). 
 
Plant material 
Laggera pterodonta (DC.) Benth was purchased from Kunming, Yunnan province of China in 
August 2002 and identified by Professor Wen-Yuan Gao. A voucher specimen (D20020818) is 
deposited at the School of Pharmacy, Tianjin Medical University, China. 
 
Extraction and isolation 
The dried aerial parts (0.85 kg) of L. pterodonta were crushed and extracted three times with 
EtOH (95%, 10 L each) at 60°C for 6 h. The EtOH extracts were concentrated under reduced 
pressure to give a residue (110 g), which was suspended in H2O, and then partitioned with 
petroleum ether, EtOAc and n-BuOH, respectively. 
 
The petroleum ether layer was concentrated to afford a residue (44 g), which was subjected to 
column chromatography with silica gel, and was eluted with increased polarity petroleum 
ether/EtOAc (8:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 100% EtOAc) to yield nine fractions. Fraction 4 
(3.9 g) was chromatographed on silica gel column (CHCl3/n-hexane, 9:1) to give four fractions 
(frs. 4.1–4.5). Fraction 4.4 (463 mg) was chromatographed on Toyopearl HW-40 
(CHCl3/MeOH, 2:1) to give 5 (295 mg). Fraction 7 (4.7 g) was chromatographed on a silica gel 
column (CHCl3/MeOH, 99:1, 98:2, 95:5, 9:1) to give five fractions (fr. 7.1–7.5). Fraction 7.4 
(1.5 g) was chromatographed on a Toyopearl HW-40 (CHCl3/MeOH, 2:1) to give four fractions 
(fr. 7.4.1–7.4.4). Fraction 7.4.1 (505 mg) was separated by HPLC (ODS, MeOH/H2O 8:2, and 
then GPC, MeOH) to give 2 (9 mg). Fraction 3 (2.5 g) was chromatographed on silica gel 
column (CHCl3/n-hexane, 9:1) to give eight fractions (fr. 3.1–3.8). Fraction 3.8 (850 mg) was 
chromatographed on a Toyopearl HW-40 (CHCl3/MeOH, 2:1) to give three fractions (fr. 3.8.1–
3.8.3). Fraction 3.8.3 (135 mg) was separated by HPLC (GPC, MeOH) to give 7 (21 mg). 
Fraction 8 (1.5 g) was chromatographed on Sephadex LH-20 (MeOH) to give four fractions (fr. 
8.1–8.4). Fraction 8.2 (298 mg) was purified by HPLC (ODS, MeOH/H2O, 8:2, and then 7:3) to 
give 1 (19 mg), 3 (7 mg), and 4 (12 mg). Fraction 8.3 (0.7 g) was chromatographed on a 
Toyopearl HW-40 (CHCl3/MeOH, 2:1) and then separated by HPLC (ODS, MeOH/H2O, 8:2) to 
give 6 (5 mg). 
 
2α-Hydroxy pterodontic acid (1) was isolated as an amorphous powder, − 2.6 (c 1.5, 
MeOH). IR (KBr) νmax cm− 1: 3398, 2929, 1695, 1623, 1456, 1375, 1253, 1149, 1043, 1022, 950, 
908, 862. EI-MS: m/z [M–H2O]+232 (41), 217 (23), 191 (38), 171 (23), 145 (74), 119 (42), 105 
(56), 91 (79), 84 (77), 77 (53), 41 (100). HREI-MS m/z 232.1439 [M–H2O]+ (calcd for 
C15H20O2, 232.1463). 1H NMR and 13C NMR (C5D5N), see table 1. 
 
Pterodolide (2) was isolated as an amorphous powder, +10.0 (c 0.2, CHCl3). IR (KBr) νmax 
cm− 1: 2956, 2925, 2853, 1755, 1730, 1703, 1454, 1373, 1262, 1248, 1146, 1089, 1013, 907, 764. 
EIMS: m/z 450 [M]+(4), 293 (8), 246 (99), 229 (40), 217 (21), 201 (49), 173 (28), 154 (12), 131 
(10), 116 (22), 105 (14), 91 (15), 43 (100). HRFTMS m/z 451.2329 [M+H]+ (calcd for 
C24H35O8, 451.2326). 1H NMR (CDCl3), see table 1; δH 3.05 (1H, q, J = 5.4 Hz), 1.29 (3H, d, 
J = 5.4 Hz), 1.52 (3H, s) (2-methyl-2,3-epoxy-butyrate); 2.00 (3H, s) (acetoxyl group); 3.44, 3.30 
(each 1H, dq, J = 11.0, 7.0 Hz), 1.20 (3H, t, J = 7.0 Hz) (ethoxyl group). 13C NMR (CDCl3), see 
table 1; δC 168.2 (s), 59.9 (s), 59.6 (d), 19.3 (q), 13.9 (q) (2-methyl-2,3-epoxy-butyric group); 
169.1 (s), 22.1 (q) (acetoxyl group); 58.7 (t), 15.2 (q) (ethoxyl group). 
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